Tracers / [47Sc]Sc-PSMA-617
[47Sc]Sc-PSMA-617
Also written as PSMA-617; Pluvicto
- Radionuclide
- Sc-47 t½ 4823.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- PSMA-targeting urea-based small molecule (PSMA-617)
- Target / mechanism
- Prostate-specific membrane antigen (PSMA) PMID 41705479
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/in111-psma617/">in111-psma617</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | >99% | >99% | PSMA-617 | 41705479 2026 Mol Pharm |
Need this precursor?We can point you to suppliers for [47Sc]Sc-PSMA-617, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68, In-111. Compound class inferred from precursor name (not stated outright) -- PMID 41705479: 'PSMA-617'. Stage set/updated at stage 23 from PMID 41705479: '[47Sc]Sc-PSMA-617 was used in PET imaging studies in LNCaP or PC-3 tumor models'.